Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1855 | PF 04691502 | PI3K and mTOR tyrosine kinase inhibitor | €90.00 | |
| 1663 | Perifosine | PI3K/Akt inhibitor | €85.00 | |
| 2610 | PDK1 inhibitor 2610 | Dual PI3K/PDPK1 inhibitor; desmethyl analogue of Axon 1282 | €125.00 | |
| 1718 | Palomid 529 | mTOR inhibitor | €90.00 | |
| 2525 | OSU 03012 | ATP-competitive PDK-1 inhibitor reducing PAK/Akt phosphorylation and cell proliferation | €95.00 | |
| 1797 | NVP-BKM120 | Class I PI3K inhibitor | €90.00 | |
| 2029 | NVP-BGT226 | Orally active dual PI3K/mTOR inhibitor | €120.00 | |
| 1520 | NVP-BBD130 | Dual PI3K and mTOR kinase inhibitor | €125.00 | |
| 3046 | MRT 67307 | TBK1 and IKKϵ inhibitor | €125.00 | |
| 3343 | ML-9 hydrochloride | MLCK, Akt and STIM1 inhibitor | €60.00 | |
| 1684 | MK 2206 dihydrochloride | Akt inhibitor (allosteric) | €80.00 | |
| 3247 | Miltefosine | PI3K/Akt inhibitor | €50.00 | |
| 2425 | MHY 1485 | mTOR activator with an inhibitory effect on autophagy | €70.00 | |
| 3098 | ME-401 | Potent, selective and orally available PI3K inhibitor (p110 δ specific) | €100.00 | |
| 3850 | M2698 | p70S6K/Akt dual inhibitor | Inquire | |
| 1366 | LY 294002 | PI3K inhibitor | €70.00 | |
| 1472 | KU-0063794 | mTOR inhibitor | €60.00 | |
| 4147 | IPI-549 | Orally bioavailable potent and selective PI3Kγ inhibitor | Inquire | |
| 4133 | IPI-145 | PI3K p110α/γ isoform specific inhibitor | Inquire | |
| 2142 | INK 128 | Potent and selective mTOR inhibitor | €110.00 | |
| 2168 | IC 87114 | Potent and highly selective inhibitor of the PI3K p110δ | €85.00 | |
| 1929 | GSK2334470 | Potent and selective PDK1 inhibitor | €95.00 | |
| 3007 | GSK 8612 | Potent and highly selective TBK1 inhibitor | €120.00 | |
| 1729 | GSK 690693 | ATP-competitive pan-Akt kinase inhibitor | €130.00 | |
| 1912 | GSK 2636771 dihydrochloride | PI3K inhibitor (p110 β specific) | €105.00 | |
| 1596 | GSK 2126458 | Dual PI3K and mTOR inhibitor | €50.00 | |
| 2460 | GSK 2110183 hydrochloride | Potent, reversible, selective, and orally bioavailable inhibitor of the Akt kinases | €105.00 | |
| 3807 | GS-9901 | Potent and isoform-selective inhibitor of PI3Kδ | Inquire | |
| 3584 | GDC-0084 | Brain-penetrant dual PI3K and mTOR inhibitor | €110.00 | |
| 4037 | GDC-0068 | Potent, APT-competitive and orally available small molecule pan-Akt inhibitor. | Inquire | |